Practice Test Geeks(CLS) Clinical Lipid Specialist Certification Practice Test
← All CLS Flashcard Decks

Therapeutic Lifestyle & Pharmacologic Interventions Flashcards

7 cards from real CLS practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Therapeutic Lifestyle & Pharmacologic Interventions flashcards as text

  1. A patient on high-intensity statin therapy has LDL-C still above goal. Which add-on therapy has demonstrated cardiovascular event reduction in a dedicated outcomes trial?

    Answer: Ezetimibe

    The IMPROVE-IT trial demonstrated that ezetimibe added to simvastatin significantly reduced major cardiovascular events compared to simvastatin alone.

  2. Which dietary fat substitution has the greatest evidence for reducing LDL-C when replacing saturated fat?

    Answer: Polyunsaturated fatty acids

    Replacing saturated fat with polyunsaturated fatty acids (PUFAs) produces the greatest LDL-C reduction and improves the LDL/HDL ratio.

  3. A patient with severe hypertriglyceridemia (TG >1000 mg/dL) is at highest immediate risk for which complication?

    Answer: Acute pancreatitis

    Severely elevated triglycerides (>1000 mg/dL) pose the greatest immediate risk of acute pancreatitis, which can be life-threatening.

  4. Inclisiran differs mechanistically from PCSK9 monoclonal antibodies in that it:

    Answer: Inhibits PCSK9 synthesis via RNA interference

    Inclisiran is a small interfering RNA (siRNA) that reduces hepatic PCSK9 synthesis, leading to sustained LDL-C lowering with twice-yearly dosing.

  5. In the TLC (Therapeutic Lifestyle Changes) diet, what is the recommended daily dietary cholesterol intake?

    Answer: < 200 mg/day

    The NCEP TLC diet recommends limiting dietary cholesterol to less than 200 mg/day to reduce LDL-C.

  6. Which statin is the most hydrophilic and is least likely to cause CNS side effects such as sleep disturbances?

    Answer: Rosuvastatin

    Rosuvastatin is the most hydrophilic statin, which limits its CNS penetration and is associated with fewer CNS-related adverse effects.

  7. A patient cannot tolerate any statin due to myopathy. Which non-statin therapy has demonstrated the most robust LDL-C reduction (up to 50-60%) as monotherapy?

    Answer: PCSK9 inhibitor (evolocumab)

    PCSK9 inhibitors like evolocumab can reduce LDL-C by 50-60% as monotherapy and are a key option for statin-intolerant patients.

How this page was made: written with AI tools. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

  1. lipidboard.org — Renewal, score validity, test delivery, exam format, time limit, fees, registration deadline, test dates · verified Oct 2026